[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.
https://doi.org/10.3322/caac.21442
|
[2]
|
Van Hilst, J., de Rooij, T., Bosscha, K., et al. (2019) Laparoscopic versus Open Pancreatoduodenectomy for Pancreatic or Periampullary Tumours (LEOPARD-2): A Multicentre, Patient-Blinded, Randomised Controlled Phase 2/3 Trial. The Lancet Gastroenterology & Hepatology, 4, 199-207. https://doi.org/10.1016/S2468-1253(19)30004-4
|
[3]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[4]
|
贾臻, 张火俊. 胰腺癌新辅助与辅助放疗进展[J]. 肿瘤学杂志, 2021, 27(2): 105-109.
|
[5]
|
Pedrazzoli, S., Dicarlo, V., Dionigi, R., et al. (1998) Standard versus Extended Lymphadenectomy Associated with Pancreatoduodenectomy in the Surgical Treatment of Adenocarcinoma of the Head of the Pancreas: A Multicenter, Prospective, Randomized Study. Annals of Surgery, 228, 508-517.
https://doi.org/10.1097/00000658-199810000-00007
|
[6]
|
Jang, J.Y., Kang, M.J., Heo, J.S., et al. (2014) A Pro-spective Randomized Controlled Study Comparing Outcomes of Standard Resection and Extended Resection, Including Dissection of the Nerve Plexus and Various Lymph Nodes, in Patients with Pancreatic Head Cancer. Annals of Surgery, 259, 656-664.
https://doi.org/10.1097/SLA.0000000000000384
|
[7]
|
Wang-Gillam, A., Li, C.P., Bodoky, G., et al. (2016) Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer after Previous Gemcita-bine-Based Therapy (NAPOLI-1): A Global, Randomised, Open-Label, Phase 3 Trial. Lancet, 387, 545-557. https://doi.org/10.1016/S0140-6736(15)00986-1
|
[8]
|
Neoptolemos, J.P., Kleeff, J., Michl, P., et al. (2018) Ther-apeutic Developments in Pancreatic Cancer: Current and Future Perspectives. Nature Reviews Gastroenterology & Hepatology, 15, 333-348.
https://doi.org/10.1038/s41575-018-0005-x
|
[9]
|
Oettle, H., Neuhaus, P., Hochhaus, A., et al. (2013) Adjuvant Chemotherapy with Gemcitabine and Long-Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA—The Journal of the American Medical Association, 310, 1473-1481. https://doi.org/10.1001/jama.2013.279201
|
[10]
|
Neoptolemos, J.P., Stocken, D.D., Bassi, C., et al. (2010) Adjuvant Chemotherapy with Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial. JAMA—The Journal of the American Medical Association, 304, 1073-1081. https://doi.org/10.1001/jama.2010.1275
|
[11]
|
Okusaka, T., Miyakawa, H., Fujii, H., et al. (2017) Updated Results from GEST Study: A Randomized, Three-Arm Phase III Study for Advanced Pancreatic Cancer. Journal of Cancer Research and Clinical Oncology, 143, 1053-1059.
https://doi.org/10.1007/s00432-017-2349-y
|
[12]
|
Sudo, K., Nakamura, K. and Yamaguchi, T. (2014) S-1 in the Treatment of Pancreatic Cancer. World Journal of Gastroenterology, 20, 15110-15118. https://doi.org/10.3748/wjg.v20.i41.15110
|
[13]
|
Huang, W.K., You, L.N., Yang, S.F., et al. (2017) S-1 for Treat-ment of Advanced Hepatocellular Carcinoma: A Systematic Review of the Literature. Contemporary Oncology, 21, 16-20. https://doi.org/10.5114/wo.2017.66653
|
[14]
|
Harada, K., Ferdous, T. and Ueyama, Y. (2017) Therapeutic Strategies with Oral Fluoropyrimidine Anticancer Agent, S-1 against Oral Cancer. The Japanese Dental Science Review, 53, 61-77. https://doi.org/10.1016/j.jdsr.2016.11.001
|
[15]
|
Yen, H.-H., Chen, C.-N., Yeh, C.-C. and Lai, I.R. (2021) Adjuvant Tegafur-Uracil (UFT) or S-1 Monotherapy for Advanced Gastric Cancer: A Single Center Experience. World Journal of Surgical Oncology, 19, Article No. 124.
https://doi.org/10.1186/s12957-021-02233-2
|
[16]
|
Shinkawa, H., Uenishi, T., Takemura, S., et al. (2015) Adjuvant S-1 Chemotherapy after Surgical Resection for Pancreatic Adenocarcinoma. Hepato-Gastroenterology, 62, 169-174.
|
[17]
|
Maeda, A., Boku, N., Fukutomi, A., et al. (2008) Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Japanese Journal of Clinical Oncology, 38, 227-229. https://doi.org/10.1093/jjco/hym178
|
[18]
|
Uesaka, K., Boku, N., Fukutomi, A., et al. (2016) Adjuvant Chemo-therapy of S-1 versus Gemcitabine for Resected Pancreatic Cancer: A Phase 3, Open-Label, Randomised, Non-Inferiority Trial (JASPAC 01). Lancet, 388, 248-257.
https://doi.org/10.1016/S0140-6736(16)30583-9
|
[19]
|
Neoptolemos, J.P., Palmer, D.H., Ghaneh, P., et al. (2017) Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet, 389, 1011-1024. https://doi.org/10.1016/S0140-6736(16)32409-6
|
[20]
|
Cunningham, D., Chau, I., Stocken, D.D., et al. (2009) Phase III Randomized Comparison of Gemcitabine versus Gemcitabine Plus Capecitabine in Patients with Advanced Pancreatic Cancer. Journal of Clinical Oncology, 27, 5513-5518. https://doi.org/10.1200/JCO.2009.24.2446
|
[21]
|
Conroy, T., Desseigne, F., Ychou, M., et al. (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. The New England Journal of Medicine, 364, 1817-1825. https://doi.org/10.1056/NEJMoa1011923
|
[22]
|
冯清波, 王小东, 刘同泰, 高媛, 姚捷. 可能切除胰腺癌新辅助治疗的现状与进展[J]. 中华肝胆外科杂志, 2020, 26(8): 632-635.
|
[23]
|
Maher, H., Jin, W., Mou, Y. and Davies, H. (2017) The Prospective of Laparoscopic Pancreaticoduodenectomy for Cancer Management. Chinese Clinical Oncology, 6, Article No. 8. https://doi.org/10.21037/cco.2017.01.03
|
[24]
|
Merkow, J., Paniccia, A. and Edil, B.H. (2015) Laparoscopic Pancreaticoduodenectomy: A Descriptive and Comparative Review. Chinese Journal of Cancer Research, 27, 368-375.
|
[25]
|
Evans, D.B., Varadhachary, G.R., Crane, C.H., et al. (2008) Preoperative Gem-citabine-Based Chemoradiation for Patients with Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology, 26, 3496-3502.
https://doi.org/10.1200/JCO.2007.15.8634
|
[26]
|
Cooper, A.B., Parmar, A.D., Riall, T.S., et al. (2015) Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates? Journal of Gastrointestinal Surgery, 19, 80-87.
https://doi.org/10.1007/s11605-014-2620-3
|
[27]
|
Matsumoto, I., Murakami, Y., Shinzeki, M., et al. (2015) Pro-posed Preoperative Risk Factors for Early Recurrence in Patients with Resectable Pancreatic Ductal Adenocarcinoma after Surgical Resection: A Multi-Center Retrospective Study. Pancreatology, 15, 674-680. https://doi.org/10.1016/j.pan.2015.09.008
|
[28]
|
Sohal, D.P.S., Duong, M., Ahmad, S.A., et al. (2021) Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncology, 7, 421-427.
https://doi.org/10.1001/jamaoncol.2020.7328
|
[29]
|
白燕南, 严茂林. 胰腺癌综合诊治指南(2018版)外科相关部分解读[J]. 中国普外基础与临床杂志, 2018, 25(6): 669-672.
|
[30]
|
Liu, X., Li, Z. and Wang, Y. (2021) Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Advanced Biology, 5, e1900236. https://doi.org/10.1002/adbi.201900236
|